The valuation of Prime Medicine’s stock, supported by a risk-adjusted net present value analysis, underpins the Buy rating, with a 12-month price target set at $10 per share. According to TipRanks, He ...

Clearmind Medicine Inc. (NASDAQ:CMND) shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. What Happened ...

Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a ...

On the financial front, Disc Medicine announced a public stock offering of approximately $178 million, led by Frazier Life Sciences and Logos Capital, to advance research and clinical development ...

Novavax Inc.’s stock tumbled 19% early Wednesday after ... according to the National Library of Medicine. Back To Top ...

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. Clearmind Medicine secures a U.S. patent for its MEAI-based binge ...

A class II risk level is given to products that "may cause temporary or medically reversible adverse health consequences." ...

Beer drinkers are more likely to have an unhealthy lifestyle than folks who prefer wine or liquor, scientists report.

The upgrade to Outperform reflects the firm's positive outlook on the stock's potential, based on the detailed financial analysis and the underlying value of Editas Medicine's technology and assets.

Barclays dropped their target price on Editas Medicine from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Bank of America raised shares of ...

Clearmind Medicine Inc. (NASDAQ ... According to data from Benzinga Pro, the stock experienced above-average trading volume of 3.60 million shares compared to its average volume of 71,163.